Dose May Matter: CYP2C19 Genotype and PPI Response in Pediatric Eosinophilic Esophagitis.
prospective_cohort · Level II
Where this comes from
- Record sourced from PubMed, PMID 42439590.
- Also identified by DOI 10.14309/ajg.0000000000004117.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Little is known about the effect of proton pump inhibitor (PPI) metabolism, based on CYP2C19 genotype, on treatment response in pediatric eosinophilic esophagitis (EoE). We conducted a cohort study of pediatric subjects with active histologic EoE treated with PPI therapy. Whole blood samples were tested for CYP2C19 genotype. Among subjects prescribed high PPI dose > 1mg/kg/day, intermediate/slow PPI metabolizers were significantly more likely to have histologic response to PPI therapy compared to normal and rapid PPI metabolizers. No ultra-rapid metabolizers responded to PPI therapy. Knowing CYP2C19 genotype may optimize PPI dose for the treatment of EoE in individual patients.